Aims: Type 1 diabetes can be complicated with neuropathy that involves immunemediated and inflammatory pathways. Glucagon-like peptide-1 receptor agonists such as liraglutide, have shown anti-inflammatory properties, and thus we hypothesized that long-term treatment with liraglutide induced diminished inflammation and thus improved neuronal function.
| INTRODUCTION
Diabetes is a chronic metabolic disorder associated with chronic lowgrade inflammation, oxidative stress and changes in endoneurial integrity, which can result in several complications such as polyneuropathy.
In type 1 diabetes, the pancreatic islet β cells are the target of an autoimmune response, which destroys the insulin producing capacity.
Different cytokines have been associated with islet mononuclear infiltrate and cell toxicity. 1 Systemic inflammation is typically quantified by assessing serum levels of proinflammatory cytokines such as tumour necrosis factor-α (TNF-α) and interleukin (IL)-1 and IL-6. Such concomitant inflammation has been associated with marked neuronal loss leading to widespread disturbances in neuronal function in neurodegenerative diseases e.g. in Alzheimer's disease. 2 In addition, in vitro and in vivo studies provide convincing evidence that glucagon-like peptide-1 (GLP-1) agonists possess anti-inflammatory and antioxidative effects, putatively mediated alterations in monocyte function, diminished macrophage infiltrations and subsequent inhibition of proinflammatory pathways. 3 Furthermore, preclinical studies of the effect of GLP-1 agonists on the central nervous system have demonstrated beneficial effects on memory, synaptic brain plasticity and glucose metabolism. 4 In addition, experimental animal studies have indicated that GLP-1 agonists (exenatide) may also exert direct neuroprotective and neurotrophic effects independent of its glycaemic effects. [5] [6] [7] For example, in diabetic and nondiabetic mice, GLP-1 receptors are present on sensory neurons, axons, Schwann cells and dorsal root ganglia.
Diabetic polyneuropathies are common and present in approximately 50% of adults with long-term diabetes, the pathogenesis of which is multifactorial including vascular, metabolic, immune mediated and inflammatory pathways. 8 The clinical manifestations of polyneuropathy are pleomorphic and are associated with substantial socioeconomic burdens, and reduced quality of life. Polyneuropathy affects classically the peripheral axons in a length dependent manner leading to classical stocking-and-glove representation and is termed diabetic symmetric polyneuropathy (DSPN). These neuropathic changes coexists often with diabetic autonomic neuropathy and alterations of the structural and functional brain processing, which may be evident as a reduction in regional grey matter volume, microstructural damage within nerve tracts, and alterations in processing of somatosensory evoked potentials (SEPs). [9] [10] [11] Despite a negative proof-ofconcept study evaluating the effect of exenatide, a GLP-1 agonist, on measures of DSPN and cardiac autonomic neuropathy (CAN) in patients with type 2 diabetes, it is, however, plausible that GLP-1 agonists via an anti-inflammatory mechanism could target the neuroinflammatory component of polyneuropathy, potentially leading to improved neuronal function of the central and peripheral nervous system in diabetes. 12, 13 Therefore, we hypothesized that treatment with a GLP-1 agonist, improves neuronal function through diminished inflammation in type 1 diabetes, independent of glucose metabolism. The primary objective was to explore the neuronal function in response to anti-inflammatory actions of liraglutide treatment and thus the secondary aim was to investigate the effect on inflammatory parameters.
What is already known about this subject
• There is no known cure to diabetic neuropathy, which may affect the central, autonomic or peripheral nervous systems and consequently reduces life expectancy and quality of life.
• In preclinical trials, glucagon-like peptide-1 agonist treatment has shown anti-inflammatory and neuroprotective effects, and thus possesses a justified treatment option in diabetic neuropathy.
• Heightened levels of interleukin-6 have been associated with reduced heart rate variability in type 1 diabetes, potentially indicating a specific importance of this cytokine in autonomic neuropathy.
What this study adds
• Liraglutide elicited a reduction in interleukin-6 in patients with long time type 1 diabetes and confirmed symmetrical polyneuropathy.
• There was a numerical reduction in other cytokines indicating anti-inflammatory actions of liraglutide, however no improvement was shown in neural function, plausibly because the polyneuropathy had reached a point beyond reversibility.
• Clinically, liraglutide induced weight loss and improved microalbuminuria, confirming compliance to the study drug.
| METHODS

| Study population
We performed a prospective, randomized, double-blinded, parallel- 
| Central neuronal assessment-electrical stimulation and evoked potentials
Electrical stimulation was applied using surface electrodes electrode was situated between AFz and Fz, and therefore the polarity is inverted (e.g. our N14 corresponds to is P14 in other work 15 ). Early cortical activation was analysed at the negative potential (N20) and the positive potential (P22), at the centro-parietal CP5 electrode contralateral to the stimulation, and the peak-to-peak amplitude was used. In a similar way the latencies and amplitude of the subcortical response (N14-P18) was analysed at the occipital midline electrode (Oz), and late cortical response (N60-P80) was assessed at the central midline electrode C1. 16
| Systemic biochemistry, inflammatory profile and macrophage function
Routine laboratory tests to monitor e.g. HbA1c, cholesterol and triglycerides were analysed at the Department of Clinical Biochemistry, Aalborg University Hospital. Fasting venous blood was collected and subsequently centrifuged at 800 g for 10 minutes at room temperature. Plasma was immediately frozen at −80°C. Levels of proinflammatory cytokines (IL1β, TNF-α, IL-6, IL-8, IL-10) were analysed by using a multiplex cytokine assay (Meso-Scale Discovery, Rockville, MD, USA) and specific macrophage markers (sCD163 and sCD206) were analysed by enzyme-linked immunosorbent assay at Department of Clinical Biochemistry at Aarhus University Hospital.
| Autonomic neuronal assessmentcardiometric derived autonomic measures
Twenty-four-hour Holter monitoring electrocardiographic recordings were undertaken (Lifecard CF; Del Mar Reynolds, Spacelabs Healthcare Inc., Snoqualmie, WA, USA), according to internationally recommended standard. 17 The initial recording period comprised a 10-minute epoch where participants were instructed to relax followed by 2 × 15-minute periods of guided respiratory rate of 15 breaths/min in the supine position followed by the same respiration rate in standing position. Blood pressure was simultaneously measured noninvasively in these 2 positions (Omron M4, Hoofddorp, Netherlands).
Orthostatic hypotension was defined as >20 mmHg reduction in systolic blood pressure on standing. Twenty-four-hour heart rate variability (HRV) was assessed (Impresario Software version 3; Spacelabs Healthcare Inc., Snoqualmie, WA, USA), deriving HRV indices from reflecting autonomic imbalance (both sympathetic and parasympathetic tone); and the root mean square of difference of successive normal R-R intervals reflecting parasympathetic tone. 18 In addition, fast
Fourier transformation provided the following frequency domain HRV indices: derived total power, very low frequency, low frequency, high frequency and the low/high frequency ratio (reflecting sympatico-vagal balance). All HRV indices were adjusted for baseline heart rate. 19 Furthermore, validated measures of cardiac vagal tone and cardiac sensitivity to the baroreflex were derived. 20 Small fibre neuropathy was measured by a computerized Thermo Tester (TSA II NeuroSensory analyser; Medoc Ltd, Ramat Yishai, Israel). The temperature increased from a baseline of 32°C to a maximum of 52°C with increments of 1°C/s. The thermode was positioned on the skin on the right volar forearm, 10 cm proximal from the wrist.
At pain tolerance threshold, the participants were told to press a button and the average of 3 successive stimulations were used for further analysis.
Loss of protective sensation was assessed by applying a standardized 26-g monofilament perpendicular to the plantar side of the first toe and a reference area on the forearm. The size of the monofilament (gram) was noted at the pain detection threshold. If no pain was evoked at the maximum size, 300 g was notified for further calculation.
| Study endpoints
The primary endpoint was the change in the early precortical N20 latency of the primary SEP elicited in response to electrical stimuli delivered to the median nerve before and after 26 weeks of placebocontrolled intervention at the titrated dose. 23 The secondary outcomes were changes in systemic proinflammatory cytokines (IL-1β, TNF-α, IL-6, IL-8 and IL-10) and specific macrophage markers (sCD163 and sCD206), subcortical evoked potentials (N14) and late cortical potentials (N60), measures of autonomic function, and standardized neurophysiological testing. Tertiary outcomes were alterations in weight, HbA1c, heart rate, blood pressure and insulin utilization.
| Statistics
The sample size was determined according to previously reported electrophysiological latencies from our laboratory. However, these results were not specific to liraglutide-induced changes. This study was powered to detect a minimal difference of 1.0 standard deviation (SD) between liraglutide and placebo in the N20 latency and HRV indices were adjusted for resting heart rate at the time of testing.
Statistical significance was inferred at a 2-tailed P-value <.05. Analyses were performed prior to unblinding, using SAS version 9.4 (SAS Institute, Cary, NC, USA).
| RESULTS
In total, 602 patients with type 1 diabetes were identified in the electronic patient records; however, 488 did not meet the specific inclusion criteria (Figure 1 ).
The study personnel assessed the 114 remaining patients for additional eligibility. Of these, 66 patients were excluded (n = 20, did not have abnormal nerve conduction velocities and n = 46 declined to participate). Ultimately, 48 patients were randomized, 9
of whom withdrew from the study due to adverse effects (7/9: severe nausea; 5/9: vomiting; 3/9: reflux; 3/9: decreased appetite).
In total 19 patients randomized to liraglutide and 20 to placebo completed the trial. Overall, 80% of patients were male, had a mean 3.1 | Primary study endpoint
| Central neuronal assessment-evoked potentials
Twenty-six weeks of intervention with liraglutide did not demonstrate changes in early precortical N-20 latency from electrically evoked brain potentials with a difference of −1.5% (95% confidence interval
[CI]: −10.0, 8.0), see Figure 2 and Supplementary Table S1 .
| Secondary endpoints
| Inflammatory profile
Liraglutide significantly reduced IL-6 (−22.6% (95%CI −38.1, −3.2)
compared to placebo with a numerical reduction in other proinflammatory cytokines and markers of macrophage function ( Figure 3 and Table 2A ).
| Central neuronal assessment-evoked potentials
There were no differences in either latency or amplitude in the upstream activation of the brain across a number of levels including sub-, early-and late-cortical activation, see Figure 2 and supplementary material.
FIGURE 1
The consort flow chart shows the progress through this prospective, randomized, double-blind, parallel-group, placebo-controlled trial Data are means (standard deviation), median (interquartile range) or n/%. eGFR = estimated glomerular filtration rate (mL/min/1.73 m 2 ); RAAS = renin angiotensin aldosterone system; HbA1c = glycated haemoglobin.
| Autonomic neuronal assessment-cardiometric derived autonomic measures
Liraglutide treatment did not elicit any alterations in cardiometrically derived autonomic measures compared to placebo (Supplementary material).
| Peripheral neuronal assessment-peripheral nerve function
Liraglutide treatment was not associated with changes in peripheral nerve function, (Table 2B ).
Liraglutide treatment resulted in a weight reduction of 3.38 kg (95%CI −5.29, −1.48, P < .001) when compared to placebo regardless of any effect on HbA1c or total insulin use. Furthermore liraglutide reduced urine albumin-to-creatinine ratio by 40.3% (95%CI: −60.6, −9.5, P = .015; for more details see Table 3 ). Models have been adjusted for baseline values of the given outcome, and adjusted for: To the best of our knowledge, this is the first time that a randomized placebo-controlled study has shown significant decrease in IL-6 in response to liraglutide treatment in humans. Although IL-6 primarily is regarded as a proinflammatory cytokine, its actions are not limited to the immune system and its regenerative properties are increasingly recognized including neuronal differentiation and regeneration, metabolic processes, and liver regeneration. 24 The current findings indicate a GLP-1-mediated reduction in macrophage infiltration and inhibition of inflammatory pathways, although it is not clear why there was a preferential effect on IL-6 rather than other proinflammatory cytokines. It is known that macrophages residing in adipose tissue are the major sources for elevated plasma IL-6 in obesity, and therefore the observed reduction in IL-6 seems directly influenced by the weight loss itself. 25 Nevertheless, heightened levels of IL-6 have been associated with reduced heart rate variability in type 1 diabetes, potentially indicating a specific importance of this cytokine in autonomic neuropathy. 26 Furthermore, elevated levels of IL-6 have been identified as an independent predictor of type 2 diabetes and associated cardiovascular events. 27, 28 In addition, it has recently been suggested that the inflammatory cascade from CRP to IL-6 provides a novel therapeutic opportunity of atheroprotection by targeting the central IL-6 signalling system and thus ultimately inhibits the IL-1β producing inflammasome. 29 Concomitantly with the reduction in IL-6 were numerical trends present in other cytokines. This is in line with the presence of GLP-1 receptors demonstrated on monocytes/macrophages and supports the reported 12% reduction of TNF-α in liraglutide treated patients with type 2 diabetes and microalbuminuria. 30 The shown reduction of microalbuminuria in the liraglutide treated group is in accordance with previous data from the larger outcome studies. 31, 32 In addition, recent findings advocate that the IL-6 pathway seems overactive in 40% of type 1 diabetes patients and that this previously has been implicated in the initiation and progression of microalbuminuria. 33 In that context, our data show a concomitantly reduction in IL-6 and microalbuminuria in type 1 diabetes and confirmed DSPN and thus may contribute to a mechanistic understanding of the liraglutide induced nephroprotection.
| DISCUSSION
The pathogenesis of diabetic neuropathies is complex and poorly understood, involving vascular, metabolic, immune-mediated and inflammatory pathways, which taken together leads to ischaemia, oxidative stress, nonenzymatic glycation of neural structures and heightened inflammatory response. 8 The microglia produces proinflammatory cytokines such as IL-6 and free radicals, which have been shown to be neurotoxic in e.g. Alzheimer's disease. 34 Furthermore, increased levels of TNF-α has been correlated to heart rate variability and CAN, 35 and are speculated to play a pathogenic role in the development and maintenance of diabetic neuropathy. 36 It is therefore intriguing to target the anti-inflammatory component of neurodegeneration, 37 39, 40 ; however, the onset of DSPN is earlier in men plausibly due to lifestyle and depletion of androgens, which exerts specific neuroprotective effects. 41, 42 Therefore, the skewed sex distribution rather represents selection bias, possibly because men have favoured participating in a resource-demanding study with many applied technologies.
Similarly, liraglutide failed to have any beneficial effect on the secondary outcomes of cardiometrically derived parameters of autonomic function and standardized neurophysiological peripheral nerve testing. Our HRV results repeated after 26 weeks are in contrast to the findings of a previous studies, which demonstrated a reduction in HRV in type 2 diabetic patients treated for 12 weeks with liraglutide. 43 It was proposed that the reduction in HRV was secondary to GLP-1 receptor activation by liraglutide in the sinoatrial node, resulting in a more chronometric heart rhythm. 43 However, reduced HRV has been shown to be associated with altered central processing within the operculum-insular network, underlining the systemic influence of diabetic neuropathy. 9 This discordance in findings may reflect differences in diabetic disease phenotype and study design. In addition, patient enrolled in the present study may suffer from manifest and irreversible CAN as 35/39 participants were diagnosed with orthostatic hypotension, suggesting co-existence of severe CAN. This finding is in accordance with a similar trial performed in adults with type 2 diabetes and mild neuropathy. 13 Finally, the tertiary outcomes showed that liraglutide in comparison to placebo induced weight loss, which confirms the drug compliance. Weight loss is considered as antiinflammatory in itself, and it has previously been shown that substantially weight reduction in morbidly obese patients induces a significant decrease in IL-6, whereas TNF-α remains unaltered. 44 In this study, 
